Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET. The call will cover a corporate update and the results for Q4 and the full year 2020. Interested participants can join by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079. The live webcast is accessible via their Investor Relations website.
Viridian focuses on developing treatments for serious diseases, notably VRDN-001, an anti-IGF-1R monoclonal antibody for thyroid eye disease.
Details
News Market Reaction – VRDN
The recorded move for VRDN in the trading session of this news was -1.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.
| Conference Call & Webcast Details | |
| Date: | Thursday, March 25, 2021 |
| Time: | 4:30 pm Eastern Time |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13717079 |
| Webcast: | https://investors.viridiantherapeutics.com/events/default.aspx |
A live webcast of the conference call can be accessed in the Investors section of Viridian Therapeutics website at https://investors.viridiantherapeutics.com
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids Viridian is headquartered in Boulder, Colorado, with additional operations in Waltham, Massachusetts. Learn more about Viridian and our programs at www.viridiantherapeutics.com.
Follow us on Twitter @ViridianThera and on LinkedIn.
Contacts:
Investors
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com
Media
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.